Particle-beam (proton & carbon-ion) radiotherapy systems
Radiotherapy with accelerated protons or carbon ions that exploits their physical dose profile — used selectively, not as a replacement for X-ray therapy, with high cost and debated cost-effectiveness; centres are planned around approvals, capital and vendor choice.
1 · What it gives
Particle-beam radiotherapy uses accelerated charged particles such as protons and carbon ions to treat tumours, exploiting their physical characteristics. The sources do not present it as a near-term replacement for conventional X-ray therapy; it is used selectively for patients who may benefit more. Steps for a centre: obtain approvals and secure capital, plan the facility and treatment-room layout, then select the system vendor.
2 · What it replaces 6
3 · How to implement 3 steps
- 1Approvals and capitalObtain approvals and secure capital before choosing a vendor.
- 2Plan the facilityPlan the engineering and treatment-room layout.
- 3Select the vendorSelect the treatment-system vendor on parameters, capacity, cost-effectiveness and maintenance supply.
4 · Who delivers
Matched suppliers (matched automatically)
| AKVA group | Norway | Services / consulting | active |
| Prometheus Materials | United States | Research / RTO | active |
| Pacific Biochar | United States | Distributor | active |
| Yara | Norway | Producer | active |
| ArSta Eco | India | Services / consulting | active |
| BC Biocarbon | Canada | Distributor | active |
| Biomas | Brazil | Not classified | active |
| Birufinery | Indonesia | Producer | active |
| Charm Industrial | United States | Producer | active |
| ECOERA AB | Sweden | Producer | active |
| FORNATURES | South Korea | Producer | active |
| GECA | Canada | Services / consulting | active |
Leading companies and institutes (from the brief)
System makers named in the sources: Ion Beam Applications, Varian, Sumitomo, Hitachi, Toshiba, Siemens and Mitsubishi. Others are matched by the portal under Medical devices & implants.
5 · Rules & route to market
about 1-2 years incl. registration trials
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
The sources reviewed on 2026-10-16 identified no the US regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.
European Union
The sources reviewed on 2026-10-16 identified no the EU regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.
China
In China devices fall under NMPA registration and marketing-licence-holder rules, plus specific approval requirements for such facilities.
6 · Money: tenders & grants
7 · Tech stack & innovations
Main risks from the sources: high cost and debated cost-effectiveness, sensitivity to positioning uncertainty and organ motion, and, in China, policy and supervision changes.
Sources 5
- Link.springer.com — link.springer.com 2026-10-16
- Ptcog.site — www.ptcog.site 2026-10-16
- Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16
- Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16
- Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16